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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.012The prostate is an androgen-sensitive organ that needs proper androgen/androgen receptor (AR) signals
for normal development. The progression of prostate diseases, including benign prostate hyperplasia
(BPH) and prostate cancer (PCa), also needs proper androgen/AR signals. Tissue recombination studies
report that stromal, but not epithelial, AR plays more critical roles via the mesenchymal-epithelial in-
teractions to inﬂuence the early process of prostate development. However, in BPH and PCa, much more
attention has been focused on epithelial AR roles. However, accumulating evidence indicates that stromal
AR is also irreplaceable and plays critical roles in prostate disease progression. Herein, we summarize the
roles of stromal AR in the development of normal prostate, BPH, and PCa, with evidence from the recent
results of in vitro cell line studies, tissue recombination experiments, and AR knockout animal models.
Current evidence suggests that stromal AR may play positive roles to promote BPH and PCa progression,
and targeting stromal AR selectively with AR degradation enhancer, ASC-J9, may allow development of
better therapies with fewer adverse effects to battle BPH and PCa. (Am J Pathol 2015, 185: 293e301;
http://dx.doi.org/10.1016/j.ajpath.2014.10.012)Supported by NIH grant CA156700 (C.C.), George Whipple Professor-
ship Endowment (C.C.), and Taiwan Ministry of Health and Welfare
Clinical Trial and Research Center of Excellence grant DOH102-TD-B-
111-004 (C.C.).
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and equity in AndroScience.The prostate contains mainly the stromal cells and epithelial
cells that are separated by base members and merged in
extracellular matrix. Stromal cells include ﬁbroblasts,
smooth muscle cells (SMCs), and other minor inﬂammatory
cells, nerve cells, and endothelial cells.
The prostate is developed from the endodermal urogenital
sinus1 that contains an outer layer of embryonic connective
tissue urogenital sinus mesenchyme (UGM) and an inner layer
of urogenital sinus epithelium (UGE).1 The initial step of
prostate development in UGM involves the differentiation of
ﬁbroblasts and SMCs,1 and in response to the UGM androgen/
androgen receptor (AR) signals, UGE can grow into the
surrounding stromal cells and develop into the prostate
epithelial cells as part of the normal prostate development.
The ability of the UGM to induce epithelial development
and the developed epithelial cells, in return, to direct UGM to
undergo differentiation, suggesting that the reciprocal devel-
opmental interactions between UGM and UGE might be
governed by androgen/AR signals, which are essential for thestigative Pathology.
.development of normal prostate, benign prostate hyperplasia
(BPH), and prostate cancer (PCa). Prostate development fac-
tors, including its proliferation, differentiation, morphogenesis,
and functional maintenance, are all inﬂuenced by androgen/AR
signals.2 Androgen/AR signals also play vital roles in the
initiation and progression of BPH and PCa,3,4 which may
require the proper interaction with various AR coregulators.2
AR is a member of the nuclear receptor superfamily that can
be activated and translocated from cytoplasm to nucleus after
binding the testosterone or dihydrotestosterone.5e7 In prostate,
AR is expressed in both epithelial and stromal tissues. The
Wen et altransactivated AR in nucleus may then function through
modulation of various downstream target genes to inﬂuence
the development and maintenance of the prostate. In addition
to inﬂuencing cell growth directly, epithelial AR and stromal
AR can also function through epithelial-mesenchymal transi-
tion (EMT) to inﬂuence prostate development. EMT is a
process by which epithelial cells lose their cell-cell adhesion
and gain migratory properties to become mesenchymal-like
and/or mesenchymal stem cells. These potent mesenchymal
cells may then differentiate into different cell types to inﬂuence
the progression of BHP8 and PCa.9
This review will focus on the discussion of the roles
of stromal AR in the development of normal prostate and
prostate diseases.AR Roles in Normal Prostate Development
Accumulating evidence suggests that androgens through AR
in embryonic stromal cells, but not in epithelial cells, direct
the development of the prostate via mesenchymal-epithelial
interactions.10
Early studies suggested that during the embryonic stage,
UGM may promote prostate development via inducing
epithelial bud formation, eliciting prostatic bud growth, and
regulating ductal branching, as well as promoting epithelial
differentiation and determining the secretory protein
expressions.11e13 More important, these UGM-mediated
functions may be through androgens/AR signals to inﬂu-
ence the normal prostate development.14 This conclusion is
further strengthened from immunostaining data showing
detection of AR only in the early UGM and not in the UGE.15
The stromal androgens/AR signals may function through
modulation of different growth factors, including ﬁbroblast
growth factors (FGFs16), keratinocyte growth factor,17
insulin-like growth factor (IGF18), and vascular endothelial
growth factor,17 to promote adjacent epithelium growth and
differentiation in a temporal and spatial manner.19 However,
so far no single growth factor was able to completely replace
the stromal AR roles, suggesting stromal AR may need to
modulate multiple factors to inﬂuence the mesenchymal-
epithelial interactions for the proper prostate development.20Evidence from in Vitro Studies
In the prostate, cell proliferation and differentiation are inﬂu-
enced by many AR-modulated growth factors, including
transforming growth factor (TGF), IGF, FGF, and epidermal
growth factor. In established primary cell lines from human
prostatic stroma, androgen inﬂuences the proliferation, dif-
ferentiation, and regression of stromal cells by regulating the
expression of TGF-b, basic FGF, AR, and SMC-speciﬁc
proteins.21 Dihydrotestosterone has a signiﬁcant stimulatory
effect on stromal cell growth via increasing the production
and/or secretion of growth factor(s), including basic FGF-like
human pituitary growth factor22 in human prostatic ﬁbroblasts294isolated from fetal prostate. Similar phenomenon in stromal
cells derived from primary culture of explanted human normal
or benign prostatic tissue is also observed.23
Androgens can induce stromal-derived keratinocyte growth
factor to stimulate prostate epithelial cell growth.23 In rat
ventral stromal cells, androgen/AR signals can stimulate
myodifferentiation of stromal cells,24 and stromal AR can
modulate Ca2þmetabolism through the direct regulation of the
Stim1 gene25 or stimulate epidermal growth factor receptor
signaling to inﬂuence the prostate development.26
Knocking down AR in prostate stromal cells (PrSCs) may
affect the expression of growth factors resulting in the
repression of prostate growth. In primary cultured cells iso-
lated from ﬁbroblast speciﬁc protein 1-Cre AR knockout
(FSP-ARKO) mice, the loss of AR in stromal ﬁbroblasts
decreases prostate development.27 Co-culturing these ARKO
stromal ﬁbroblasts with the prostate epithelial BPH-1 cells
can then decrease the growth of BPH-1 cells, with decreased
expression of various growth factors, including IGF-1, FGF-
2, FGF-7, FGF-9, FGF-10, vascular endothelial growth fac-
tor-b, and placental growth factor in the stromal ﬁbroblasts.27
Knocking down AR in primary cultured cells suppresses
prostate growth in primary cultured cells isolated from mice
with AR knocked out in the stromal SMCs (SM-ARKO).
However, instead of functioning through modulation of
many growth factors, AR in the SMC is more speciﬁc and
modulates only IGF-1 signaling.28 In studies with immor-
talized PrSCs from wild-type (WT) mice and selective
double-knockout AR (dARKO) mice, PrSCs from WT mice
promote prostate epithelium growth signiﬁcantly compared
with those from dARKO mice.18 Stromal AR might function
through the modulation of IGF-1, placental growth factor,
and secreted phosphoprotein-1 to inﬂuence epithelial cell
growth.18 Together, results from various stromal cell lines
studies conclude that stromal AR may play essential roles for
the prostate development.
UGM-UGE Tissue Recombination Approaches in
Prostate Development
Tissue recombination techniques have been used for>50 years
to study the cellular biological features of both developing and
adult organs. The earlier studies for the prostate recombination
technique were conducted by Cunha et al,29 who evaluated the
mesenchymal induction of prostatic epithelium. By using renal
capsule implementation of tissue recombinants,30 it was
demonstrated that AR in stromal, but not in epithelial, cells
plays essential roles for the prostate development via inﬂuence
of ductal morphogenesis, epithelial differentiation, apoptosis,
and proliferation. In tissue recombinants of mesenchyme and
epithelial cells from WT and AR-deﬁcient testicular femini-
zation (Tfm) mice, tissue recombinants composed of Tfm-
UGM þ Tfm-epithelium fail to form prostate even in the
presence of androgens. However, WT-UGM þ WT-epithe-
lium tissue recombinants form prostate in response to andro-
gens.31 More important, Tfm-UGM þ WT-epithelium tissueajp.amjpathol.org - The American Journal of Pathology
Figure 1 Stromal androgen receptor (AR) plays critical roles in the
development of prostate. Recombination experiments and AR knockout animal
models reveal that androgen through AR in embryonic stromal cells, but not AR
in epithelial cells, directs the development of the prostate via mesenchymal-
epithelial interactions. Some other growth factors, such as keratinocyte
growth factor (KGF), ﬁbroblast growth factors (FGFs), insulin-like growth
factor-1 (IGF-1), vascular endothelial growth factor b (VEGF-b), and trans-
forming growth factor (TGF), are involved in this process.
Stromal AR Roles in Prostaterecombinants fail to develop prostate in the presence of an-
drogens, suggesting a critical role of mesenchymal AR, but not
epithelium AR, in prostate development. This conclusion was
further conﬁrmed in the reciprocal WT-UGM þ Tfm-epithe-
lium tissue recombinant study in which AR-deﬁcient Tfm
epithelium underwent androgen-dependent ductal morpho-
genesis, epithelial proliferation, and columnar cytodifferentia-
tion, thus forming glandular epithelium resembling the
prostate.20
Together, results from tissue recombinant experiments
concluded that many androgenic effects on prostatic epithelial
development require the paracrine action of AR-positive
mesenchyme. Even later analysis of Tfm/WT tissue recombi-
nants also revealed that epithelial AR might also play some
roles to induce some AR downstream secretory proteins.32
Evidence from in Vivo Mouse Models
ARKO mouse models with selective knockout of AR in
either prostate epithelial or stromal cells27,33 also help us
better understand the speciﬁc roles of stromal AR in prostate
development.
By using the Cre-loxP system to generate the ﬂoxed AR
mice, and then mating with FSP1 Cre mice, Yu et al27 suc-
cessfully generated male mice with the AR gene selectively
deleted in prostate stromalﬁbroblasts (named FSP-ARKO), and
reported the ventral prostate lobes of FSP-ARKO mice to be
lighter than WT littermates. Tissue histological analysis of
ventral prostate lobe shows changed epithelial cells with more
cuboidal and ﬂattened shapes in prostate ducts of FSP-ARKO
mice; the WT prostate epithelial cells remain columnar. These
results suggested that knocking out AR in prostate stromal
ﬁbroblasts might reduce epithelial differentiation in prostate.
Proliferation reduces with increased apoptosis in the FSP-
ARKO ventral prostates. These results suggest that AR in
prostate stromal ﬁbroblasts plays positive roles to stimulate the
prostate development.
In SM-ARKO mice, the prostates of SM-ARKO mice
have no signiﬁcant difference in gross appearance and
branching morphogenesis compared to WT mice. However,
hematoxylin and eosin staining shows defective structures in
the SM-ARKO mice prostates, suggesting that knocking
down AR might result in fewer epithelial in-foldings into the
lumens. The morphological changes of SM-ARKO mouse
prostates are due to the defective epithelium proliferation,
which is mainly mediated by stromal SMC-secreted IGF-1.
IGF-1 is a key AR-modulated growth factor in prostate for
proliferation and morphogenesis.34e36 Knocking down AR
in the SM-ARKO mice signiﬁcantly suppresses IGF-1
expression in anterior and ventral prostates.
In double-stromal AR knockout mice (with selectively
deleted AR in both stromal ﬁbroblasts and SMCs, named
dARKO), the size of the anterior prostate lobes is signiﬁcantly
reduced.Decreased proliferation and increased apoptosis in the
epithelial cells of dARKO mouse anterior prostates are also
observed.18 Dissection of themechanism in the PrSCs, isolatedThe American Journal of Pathology - ajp.amjpathol.orgfrom dARKOmice, conﬁrms that IGF-1 is the key mediator of
stromal AR function for normal prostate growth.18
Together, results from various ARKO mice conclude that
AR in prostate stromal ﬁbroblasts or SMCs plays positive
roles to stimulate normal prostate development (Figure 1).
AR Roles in BPH
Human prostate consists of three distinct histological zones:
central, peripheral, and transition. Nearly all clinically signiﬁ-
cant BPH develops in the transition zone of the prostate.
Macroscopic growth of the transition zone can cause narrowing
of the urethra as it passes through the prostate, leading to a
bladder outlet obstruction, which may affect the ﬂow of urine.
BPH is the most common benign neoplasm in American men
and affects almost three-quarters of men during the seventh
decade of life.37 BPH-induced lower urinary tract symptoms,
including bladder outlet obstruction, contribute to a spectrum of
urinary voiding problems that can signiﬁcantly affect quality of
life. The etiology of BPH remains unclear. An early study
indicated that BPH contains mainly stromal cells (88.4%), with
only 9.0% epithelial cells,38 suggesting the stromal cells may
play more important roles in the development of BPH, even
though both the stromal and epithelial components are involved
in the development of BPH. McNeal39 hypothesized that the
reversion of the stroma to an embryonic phenotype and the
formation of hyperplastic stromal nodules are the earlier events
in BPH, and the de novo formation of epithelial glands in BPH
is a later event, which is induced by paracrine factors from the
stromal nodules, emphasizing that stroma may play an
important role in inﬂuencing BPH development.
The stromal androgens/AR signals may inﬂuence the
initiation and progression of BPH via alteration of the
various growth factors in the paracrine and/or autocrine
manner.40,41 For example, factors involved in alteration of
cell proliferation/differentiation42 or stem cell population,43
as well as factors involved in the EMT8 or inﬂammation/
immune tolerance,44,45 have been suggested to be directly or295
Wen et alindirectly linked to the AR. Therefore, targeting androgens/
AR signals continue to play key roles in battling the pro-
gression of BPH.38,46
Evidence from in Vitro Studies
There are three reported mechanisms by which prostate AR
promotes the development of BPH. The ﬁrst mechanism is
to inﬂuence the proliferation of prostate cells directly from
stromal AR. AR tissue compartment assays indicate that
BPH tissue has much higher AR expression compared to
adjacent normal glandular tissue.47,48 In epithelial cells and
stromal cells isolated from BPH tissue, androgen can
induce the expression of FGF-10 in stromal cells, but not
epithelial cells, to stimulate human prostatic epithelial
proliferation.49 In primary cultured and PrSC stromal cell
lines, stromal AR might play positive roles to promote
epithelial cell growth, and targeting AR signals in stromal
cells can suppress the growth of BPH cells, suggesting that
AR in stromal cells may play positive roles to promote
BPH development.27,28,50
The second mechanism involves targeting epithelial AR to
inﬂuence BPH development via modulation of EMT.51 EMT,
which is characterized by decrease of epithelial markers,
including E-cadherin, and increase of mesenchymal (stromal)
factors, including N-cadherin, vimentin, and Snail,52 is a
continual progression of epithelial cells to acquire the motile
characteristics of mesenchymal cells.51 EMT might inﬂuence
cells in regions of the ductal epithelium, resulting in loss of their
polarization, with little E-cadherin expression.8 Snail2/Slug is
an important transcription factor for TGF-b1einduced EMT in
the development of BPH.53 AR in BPH-1 and mPrE cells
signiﬁcantly increases macrophage THP-1 and RAW264.7 cell
migration in co-cultures.54 These recruited macrophages might
then function through enhanced EMT to promote BPH devel-
opment and progression, suggesting that AR in prostate
epithelial cells might play a positive role in promoting
macrophage-mediated EMT to enhance BPH development.54
The third mechanism involves stromal AR functions
through the recruitment of macrophages to enhance the stro-
mal cell proliferation.55 Early studies demonstrated that
inﬂammation is a potential causative factor for BPH devel-
opment and progression.44,45,56 In a co-culture system, mouse
PrSCs have the capacity to recruit more inﬁltrating macro-
phage RAW264.7 cells, which can then enhance stromal cell
proliferation.55 Mouse PrSCs may secrete chemokine ligand 3
as an AR downstream target to inﬂuence macrophage
recruitment, and targeting ARechemokine ligand 3 signals
may suppress BPH development via interruption of macro-
phage inﬁltration.55
Together, AR may function through either stromal AR
to directly promote BPH development or epithelial cells to
recruit macrophages to enhance EMT to inﬂuence BPH
development. In addition, AR may work via recruitment
of macrophages directly to stromal cells to promote BPH
development.296Evidence from Tissue Recombination Approaches
Because several key factors from BPH microenvironment
and interactions between epithelium and stroma are not easy
to study via the in vitro cell line system, the tissue recom-
bination approaches were developed to better evaluate the
AR roles in the BPH microenvironment for their impact on
epithelial-stromal interactions.
Use of tissue recombination approaches to compare the
stromal cells from the peripheral zone of BPH versus normal
prostate to induce the growth of epithelial BPH-1 cells
revealed that BPH-1 cells mixed with stromal cells isolated
from BPH, and not from normal prostate, can generate the
grafts with proper development.57 Histological examination
of these grafts revealed densely packed, well-organized,
tubular epithelium with minimal stroma, sharply demar-
cated from the surrounding renal tissue. Stromal AR, and
not epithelium AR, is critical in BPH development.58
Evidence from ARKO Mouse Models
By using prostate stromal double-ARKO (AR was knocked
out in both ﬁbroblasts and SMCs) mice to mate with the
prolactin transgenic mice, Lai et al59 generated the ﬁrst BPH
mouse model (dARKO/prolactin transgenic) that selectively
deleted AR in stromal ﬁbroblasts and SMCs. They showed
that loss of AR in stromal ﬁbroblasts and SMCs can result in
the development of the smaller prostates with a lower pro-
liferative index, better urination function, and normal
bladder volume.59
Prolactin-induced hyperplastic prostate growth involves
the epithelial-stromal interaction. Epithelial autonomous
prolactin/prolactin receptoregranulocyte macrophage col-
ony stimulating factor signaling in a paracrine manner to
facilitate stromal cell growth, and stromal AR, can modulate
granulocyte colony stimulating factoreSTAT3 signaling
to control epithelium cell growth. These ﬁndings were
conﬁrmed using single AR knockout from ﬁbroblasts or
SMC mouse models. Previous ﬁndings that the stromal AR
might play positive roles to promote BPH development
were further validated in speciﬁc SMC ARKO mice60;
knocking out SMC AR in adult male mouse prostate results
in dramatically decreased anterior prostate lobe, dorsolateral
prostate lobe, and ventral prostate lobe weights.
Together, results from in vivo mice studies conﬁrm the
data from in vitro cell lines and tissue recombination studies
showing that the AR in stromal smooth muscle and ﬁbro-
blasts is the key player in promoting BPH development via
modulating the epithelial-stromal interaction (Figure 2).
Clinically, the most inconvenient symptoms induced by
BPH are lower urinary tract symptoms that may be treated
by either a-blockers or 5a-reductase inhibitors to suppress
testosterone conversion to more potent dihydrotestoster-
one. However, not all of the patients are sensitive to these
therapies and some still need surgery. Further clinical trials
to prove the above conclusion showing AR in stromal andajp.amjpathol.org - The American Journal of Pathology
Figure 2 Stromal androgen receptor (AR) promotes the progression of
benign prostate hyperplasia (BPH). Stromal AR can affect the progression
of BPH via promoting prostate epithelial cell growth, prostate stromal cell
growth, epithelial-mesenchymal transition (EMT) progress, and the
recruitment of macrophage. CCL, chemokine ligand; FGF, ﬁbroblast growth
factor; GMCSF, granulocyte colony stimulating factor; TGF, transforming
growth factor.
Stromal AR Roles in Prostateepithelial cells may play key roles in promoting develop-
ment of BPH, which may help us develop new and better
therapies via targeting AR in stromal and epithelial
cells.54,61Figure 3 Stromal androgen receptor (AR) promotes the progression of
prostate cancer (PCa). Evidence from in vitro cell line studies, recombina-
tion experiments, and AR knockout animal models demonstrates that
stromal AR can promote PCa growth, metastasis, and tumorigenesis. FGF,
ﬁbroblast growth factor; HGF, hepatocyte growth factor; IGF, insulin-like
growth factor; MIP, macrophage inﬂammatory protein; SDF, stromal
derived factor; TGF, transforming growth factor.Stromal AR Roles in PCa
PCa is the leading cancer in men in the United States,62 and it
may affect one-sixth of men.63 PCa was proved to originate
from epithelial cells.62 Since the discovery of Huggins and
Hodges in 1941,64 the vital roles of androgens/AR signals have
been realized well, and androgen deprivation therapy to prevent
or reduce androgen binding to AR, which may suppress tumor
progression in most of the cases in the ﬁrst 1 to 2 years,65 has
been the standard therapy to treat the advanced PCa.
Prostate tumorigenesis has been regarded as a largely
cell-autonomous process that may involve genetically
transformed epithelial cells. Interestingly, although the
epithelial AR roles in the inﬂuence of PCa development
have been well studied, the stromal AR roles in the devel-
opment of PCa remain relatively unclear.66e68
PCa stroma is composed of ﬁbroblasts, SMCs, extracel-
lular matrix, and other inﬁltrating cells in the prostate tumor
microenvironment. Normal prostate stromal compartment
has the inherent plasticity to respond rapidly to emerging
situations, including disrupted homeostasis with tumor
development. During emerging situations, stromal cells may
alter the phenotypic and genotypic changes to become the
so-called reactive stroma,69 which mainly includes the
changes of SMA and activation of carcinoma-associated
ﬁbroblasts (CAFs) or myoﬁbroblasts.
SMCs, one of the main components of stromal cells, ex-
press AR and respond to androgens to maintain the highly
differentiated secretory epithelium via homeostatic stromal-
epithelial interactions in PCa.70 The ﬁbroblasts, another main
component of stromal cells, can be inﬂuenced/activated by the
surrounding cancer epithelial cells,71 and in return, these
ﬁbroblasts can then potentially promote the growth and
invasion of PCa.72 Interestingly, the phenotypes of these
activated ﬁbroblasts (named CAFs) are more closely related toThe American Journal of Pathology - ajp.amjpathol.orgthe myoﬁbroblasts, and may function through their AR to
promote the PCa cell growth and invasion.73
Evidence from in Vitro Studies
To analyze the stromal AR roles in PCa development, the
immortalized CAFs were co-cultured with the PCa epithelial
PC-3 cells; the capability of CAFs to promote PC-3 cell pro-
liferation and invasion is interrupted by knocking down AR,
which involves the modulation of the expression of IGF-1,
FGF7, FGF10, stromal derived factor 1, hepatocyte growth
factor, and TGF-b2.73 These data suggested that the AR in
CAFs might be able to promote PCa epithelial growth and
invasion via regulating the expression of the growth factors.73
Via transfecting a functional AR-cDNA into the immortal-
ized human PrSCWPMY-1 (namedWPMY-AR),WPMY-AR
cells were reported to be more responsive to dihydrotestoster-
one stimulation, which results in better modulation of AR target
genes, transcribing TGF-b, Wnt, hedgehog, and mitogen-
activated protein kinase.74 These genes are also involved in
the stromal-epithelial cross talk. The consequences of altering
these stromal AR-mediated signals might promote the epithelial
(LNCaP) cell growth.
Interestingly, opposite results for the stromal AR roles in
PCa progressionwere also reported. AR levels decrease in PCa
tumor-surrounding stromal cells, especially in androgen-
independent cancers.75 By using two different telomerase-
immortalized human stromal cell lines, either AR positive or
AR negative, it was reported that stromal cells lacking AR
might promote the PCa epithelial cell proliferation and inva-
sion.75 Furthermore, adjacent stromal AR expression nega-
tively correlates with progression of PCa: the lower expression
of AR in adjacent stroma is linked to the early relapse in PCa.76
Evidence from the Tissue Recombination Approaches
The concept that stromal cells may play a role in carcino-
genesis was also proved by the tissue recombination studies.11
By using tissue recombination models in rats, Wang et al77
demonstrated that nontumorigenic human prostatic epithelial
BPH-1 cells with prostate UGM recombinants would develop297
Wen et althe invasive carcinomas in the presence of testosterone pro-
pionate (T) and 17-b-estradiol (E2). In contrast, the epithelial
cells might lead to cell apoptosis when the recombinants are
not treated with T þ E2 or host mice are castrated. These re-
sults suggest that the nontumorigenic BPH-1 cells can undergo
hormonal carcinogenesis in response to T þ E2 stimulation.
However, although BPH-1 cells can survive and grow in the
absence of UGM, they could not form the tumors or organized
structures, suggesting that the PrSCs play an important role in
mediating hormonal carcinogenesis.77 Because BPH-1 cells
express little AR and ER, whereas rat UGMs express both AR
and ERa, it is likely that T þ E2 may function through the
stromal AR and ERa to promote prostate tumorigenesis.78
Interestingly, T þ E2 treatment promotes the metastases
of murine UGM1 and BPH-1 recombinants, leading to
carcinoma.79 Tissue recombinants with AR-negative stro-
mal cells derived from mouse UGM and AR-negative
human benign prostatic epithelial cells fail to develop into
tumors. In contrast, tissue recombinants composed of WT
stromal cells and WT epithelial cells develop into much
larger and invasive tumors.79
In tissue recombination of human prostate WPMY1
stromal cells with human PCa epithelial PC-3 cells, the
stromal AR might function as a stimulator in PCa cell
growth and metastases in the orthotopic xenografted
prostate tumors. These data suggest that stromal AR
might play important roles in the PCa initiation and
progression.
Evidence from in Vivo Mouse Models
Tissue-speciﬁc AR knockout mouse models80 were also
applied to prove the essential roles of stromal-epithelial
interaction for the PCa development. Niu et al4 generated
inducible ARKO-TRAMP and prostate epithelial-speciﬁc
ARKO TRAMP mouse models, in which the AR was
knocked out in both, or separately, in prostate epithelial and
stromal cells. The results showed that in inducible ARKO-
TRAMP mice, knocking out AR in both epithelial and stro-
mal cells at earlier stages results in smaller primary prostate
tumors with lower proliferation rates. And in prostate
epithelial-speciﬁc ARKO-TRAMP mice, knockout of prostate
epithelium AR results in larger primary prostate tumors with
higher proliferation rates. These results indicate that the
prostate stromal AR might play more important roles than the
epithelial AR to promote primary tumor proliferation at the
early stages of tumor development.
In the established animal model with AR deletion in
stromal ﬁbromuscular cells (dARKO; AR knockout in ﬁ-
broblasts and SMCs), loss of stromal ﬁbromuscular AR
suppresses prostate tumorigenesis development.80 Stromal
AR plays roles in the alterations of the tumor microenvi-
ronments, such as extracellular matrix remodeling, angio-
genesis, and immune cell inﬁltration. By comparing the
stromal cells isolated from WT mice and stromal cells from
ARKO mice, they further proved that stromal AR was able to298regulate proinﬂammatory cytokine/chemokine expression
[eg, macrophage inﬂammatory protein (Mip)-1a, Mip-1b,
Mip-2, and Il-10] to affect immune cell recruitment and
modulate inﬂammatory responses in mouse prostate. For
example, AR may cooperate with NF-kB to activate MIP-1b
promoter (Ccl4) after Il-1b stimulation, instead of directly
binding to Mip-1b promoter80 (Figure 3).Conclusions and Perspective
Some studies demonstrated that epithelial AR in PCa
functions can be opposite and complicated.81,82 These
opposite epithelial AR roles might lead to different func-
tions, which explains why androgen deprivation therapy
cannot completely suppress PCa.81 In contrast, stromal AR
seems to play more consistent roles. At the embryonic
phase, stromal AR may promote prostate development via
inducing epithelial bud formation, eliciting prostatic bud
growth, and regulating ductal branching, as well as pro-
moting epithelial differentiation and determining the secre-
tory protein expressions.11e13 Stromal AR also can promote
the initiation and progression of BPH through many
mechanisms.49,55 Similar to BPH, the positive roles of
stromal AR in PCa are well demonstrated.4,83
The conclusion that stromal AR plays key roles in pro-
moting the development of BPH and PCa suggests that tar-
geting stromal AR can provide a potential therapeutic
approach to suppress the progression of BPH and PCa. ASC-
J9, a newly developed AR degradation enhancer, degrades AR
in selective cells via interruption of interaction between AR
and selective AR coregulator ARA55 in stromal cells.84 Early
studies suggest that AR coregulator ARA55 can bind to WT
AR and mutant AR (named mART877S; point mutation
threonine to serine at codon 877) in a ligand-dependent
manner to enhance their transcriptional activities85 and inﬂu-
ence the progression of PCa.86 ASC-J9 has been well proved
to suppress the progression of BPH via degradation of WT AR
and mutant AR in the prostate. Multiple mechanisms are
involved, including the suppression of macrophage-induced
PrSCs proliferation,55 EMT-induced BPH,54 prolactin-driven
BPH,59 and alteration of branching morphogenesis.18 Simi-
larly, the effect of targeting stromal AR-ARA55 interaction to
suppress PCa via ASC-J9 might involve the interruption of
TGF-beSmad3ematrix metalloproteinase 9 signals,87 inﬁl-
trating macrophage-chemokine ligand 2-STAT3 signals.88
In conclusion, results from above studies suggest that
targeting stromal AR may help us develop some new ther-
apeutic approaches to better suppress prostate diseases.References
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